Biomarker candidates of neurodegeneration in Parkinson’s disease for the evaluation of disease-modifying therapeutics
Manfred Gerlach(Universitätsklinikum Würzburg), Daniela Berg(Christian-Albrechts-Universität zu Kiel), Torsten Reum(Boehringer Ingelheim (Germany)), Johannes Streffer(University of Antwerp), Harald Hampel(Sorbonne Université), Lucas Rems(Federal Institute for Drugs and Medical Devices), Karl Broich(Federal Institute for Drugs and Medical Devices), Walter Maetzler(Christian-Albrechts-Universität zu Kiel), Peter Riederer(University of Würzburg), Albrecht Stöffler
Cited by 73
Related Papers
MDS clinical diagnostic criteria for Parkinson's disease
|Movement Disorders|2015|7.4k
Multicenter Analysis of Glucocerebrosidase Mutations in Parkinson's Disease
|New England Journal of Medicine|2009|2.1k
Genome-wide association study reveals genetic risk underlying Parkinson's disease
|Nature Genetics|2009|2k
Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria
|Alzheimer s & Dementia|2016|1.9k